About this trial
Heart valve diseases are the most common cause of mortality and morbidity after coronary artery disease, hypertension, and heart failure. In patients with mitral stenosis, the narrowed valve restricts blood flow, causing symptoms such as shortness of breath, fatigue, exertional dyspnea, orthopnea, and paroxysmal nocturnal dyspnea. These patients may experience decreased exercise capacity and physical activity levels, deterioration in quality of life, and deterioration in respiratory function. When reviewing the literature, we see that the study groups evaluating these factors are generally not homogeneous, and most studies conducted in patients with mitral stenosis evaluate patients who have undergone percutaneous mitral balloon valvuloplasty.
Eligibility criteria
Qualifiers
Between the ages of 18-80
Patients who have undergone mitral valve intervention due to mitral stenosis
At least 3 months have passed since the intervention
Between the ages of 18 and 80
Disqualifiers
Patients who have undergone aortic valve intervention other than mitral valve intervention
Acute infection
Orthopedic, neurological or psychological disorders that will affect functional capacity
diagnosed chronic disease,
Trial design
Treatments tested in this trial
- Not listed